Cardiology Xagena
Mixed effects of fish oil supplementation on the risks of atrial fibrillation were observed in several large-scale randomized controlled trials.
Whether this relationship would be modified by genetic atrial fibrillation risk, baseline cardiovascular disease ( CVD ) status and background oily fish consumption is unknown.
Researchers have included 468665 participants without atrial fibrillation at baseline from the UK Biobank cohort.
The association between fish oil supplementation and the atrial fibrillation risk was assessed in the study cohort and in several subgroups, including genetic atrial fibrillation predisposition, baseline cardiovascular disease status and background oily fish consumption.
During a median follow-up of 11.1 years, fish oil users had a higher rate of incident atrial fibrillation ( 6.2% vs 5.2%, adjusted hazard ratio [ HR ] of 1.10 and 95% confidence interval [ CI ] 1.07, 1.13 ).
Compared to non-users, fish oil users had a higher rate of incident atrial fibrillation in the low ( 3.7% vs 3.0%, P = 0.02 ), intermediate ( 5.8% vs 4.8%, P less than 0.0001 ) and high ( 9.8% vs 8.1%, P less than 0.0001 ) genetic atrial fibrillation risk groups.
In participants without cardiovascular disease at baseline, fish oil users had a higher rate of incident atrial fibrillation ( 5.3% vs 4.1%, P less than 0.0001 ), which was not observed in participants with cardiovascular disease at baseline ( 11.6% vs 11.1%, P = 0.56 ), with significant interaction ( P-interaction less than 0.0001 ).
The association between fish oil supplementation and the atrial fibrillation risk was not modified by background oily fish consumption ( P-interaction = 0.62 ).
In conclusion, habitual fish oil supplementation was associated with the risk of incident atrial fibrillation, regardless of genetic atrial fibrillation predisposition and background oily fish consumption.
This association was observed only in individuals without cardiovascular disease at baseline. ( Xagena )
Zhang J et al, Eur J Prev Cardiol 2022; Online ahead of print
XagenaMedicine_2022
